▶ 調査レポート

PEG修飾薬の世界市場見通し2023年-2029年

• 英文タイトル:PEG-modified Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。PEG修飾薬の世界市場見通し2023年-2029年 / PEG-modified Drugs Market, Global Outlook and Forecast 2023-2029 / MRC2312MG10966資料のイメージです。• レポートコード:MRC2312MG10966
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、107ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥481,000 (USD3,250)▷ お問い合わせ
  Enterprise User¥721,500 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界のPEG修飾薬市場規模と予測を収録しています。・世界のPEG修飾薬市場:売上、2018年-2023年、2024年-2029年
・世界のPEG修飾薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のPEG修飾薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「PEGアミド化」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

PEG修飾薬のグローバル主要企業は、Merck Sharp & Dohme、 Baxalta Inc.、 Amgen Inc.、 Roche、 UCB S.A.、 Enzon、 Horizon Pharma Plc、 Biogen Inc.、 Qilu Pharmaceutical Co., Ltd.、 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.、 Changchun Genescience Pharmaceutical Co., Ltd.、 Xiamen Amoytop Biotech Co., Ltd.、 Jiangsu Hengrui Pharmaceuticals Co., Ltd.、 Hansoh Pharmaceuticak Group Co.,Ltd.、 SunBio、 Xiamen Sano banger Biotechnology Co., Ltdなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、PEG修飾薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のPEG修飾薬市場:タイプ別、2018年-2023年、2024年-2029年
世界のPEG修飾薬市場:タイプ別市場シェア、2022年
・PEGアミド化、PEG化、PEGペプチド化、PEGエーテル化、その他

世界のPEG修飾薬市場:用途別、2018年-2023年、2024年-2029年
世界のPEG修飾薬市場:用途別市場シェア、2022年
・がん治療、糖尿病治療、免疫調節、抗炎症治療、その他

世界のPEG修飾薬市場:地域・国別、2018年-2023年、2024年-2029年
世界のPEG修飾薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるPEG修飾薬のグローバル売上、2018年-2023年
・主要企業におけるPEG修飾薬のグローバル売上シェア、2022年
・主要企業におけるPEG修飾薬のグローバル販売量、2018年-2023年
・主要企業におけるPEG修飾薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Merck Sharp & Dohme、 Baxalta Inc.、 Amgen Inc.、 Roche、 UCB S.A.、 Enzon、 Horizon Pharma Plc、 Biogen Inc.、 Qilu Pharmaceutical Co., Ltd.、 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.、 Changchun Genescience Pharmaceutical Co., Ltd.、 Xiamen Amoytop Biotech Co., Ltd.、 Jiangsu Hengrui Pharmaceuticals Co., Ltd.、 Hansoh Pharmaceuticak Group Co.,Ltd.、 SunBio、 Xiamen Sano banger Biotechnology Co., Ltd

*************************************************************

・調査・分析レポートの概要
PEG修飾薬市場の定義
市場セグメント
世界のPEG修飾薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のPEG修飾薬市場規模
世界のPEG修飾薬市場規模:2022年 VS 2029年
世界のPEG修飾薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのPEG修飾薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のPEG修飾薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:PEGアミド化、PEG化、PEGペプチド化、PEGエーテル化、その他
PEG修飾薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:がん治療、糖尿病治療、免疫調節、抗炎症治療、その他
PEG修飾薬の用途別グローバル売上・予測

・地域別市場分析
地域別PEG修飾薬市場規模 2022年と2029年
地域別PEG修飾薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Merck Sharp & Dohme、 Baxalta Inc.、 Amgen Inc.、 Roche、 UCB S.A.、 Enzon、 Horizon Pharma Plc、 Biogen Inc.、 Qilu Pharmaceutical Co., Ltd.、 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.、 Changchun Genescience Pharmaceutical Co., Ltd.、 Xiamen Amoytop Biotech Co., Ltd.、 Jiangsu Hengrui Pharmaceuticals Co., Ltd.、 Hansoh Pharmaceuticak Group Co.,Ltd.、 SunBio、 Xiamen Sano banger Biotechnology Co., Ltd
...

This research report provides a comprehensive analysis of the PEG-modified Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global PEG-modified Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of PEG-modified Drugs, challenges faced by the industry, and potential opportunities for market players.
The global PEG-modified Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The PEG-modified Drugs market presents opportunities for various stakeholders, including Cancer Treatment, Diabetes Treatment. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in PEG-modified Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global PEG-modified Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the PEG-modified Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the PEG-modified Drugs market.
Market Overview: The report provides a comprehensive overview of the PEG-modified Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., PEG Amidation, PEGylation), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the PEG-modified Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the PEG-modified Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the PEG-modified Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the PEG-modified Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the PEG-modified Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the PEG-modified Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for PEG-modified Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the PEG-modified Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
PEG-modified Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Market segment by Application
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
Global PEG-modified Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of PEG-modified Drugs, market overview.
Chapter 2: Global PEG-modified Drugs market size in revenue.
Chapter 3: Detailed analysis of PEG-modified Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PEG-modified Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 PEG-modified Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PEG-modified Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PEG-modified Drugs Overall Market Size
2.1 Global PEG-modified Drugs Market Size: 2022 VS 2029
2.2 Global PEG-modified Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top PEG-modified Drugs Players in Global Market
3.2 Top Global PEG-modified Drugs Companies Ranked by Revenue
3.3 Global PEG-modified Drugs Revenue by Companies
3.4 Top 3 and Top 5 PEG-modified Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies PEG-modified Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 PEG-modified Drugs Players in Global Market
3.6.1 List of Global Tier 1 PEG-modified Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 PEG-modified Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global PEG-modified Drugs Market Size Markets, 2022 & 2029
4.1.2 PEG Amidation
4.1.3 PEGylation
4.1.4 PEG Peptidation
4.1.5 PEG Etherification
4.1.6 Other Combinations
4.2 By Type – Global PEG-modified Drugs Revenue & Forecasts
4.2.1 By Type – Global PEG-modified Drugs Revenue, 2018-2023
4.2.2 By Type – Global PEG-modified Drugs Revenue, 2024-2029
4.2.3 By Type – Global PEG-modified Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global PEG-modified Drugs Market Size, 2022 & 2029
5.1.2 Cancer Treatment
5.1.3 Diabetes Treatment
5.1.4 Immunomodulatory
5.1.5 Anti-inflammatory Treatment
5.1.6 Others
5.2 By Application – Global PEG-modified Drugs Revenue & Forecasts
5.2.1 By Application – Global PEG-modified Drugs Revenue, 2018-2023
5.2.2 By Application – Global PEG-modified Drugs Revenue, 2024-2029
5.2.3 By Application – Global PEG-modified Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global PEG-modified Drugs Market Size, 2022 & 2029
6.2 By Region – Global PEG-modified Drugs Revenue & Forecasts
6.2.1 By Region – Global PEG-modified Drugs Revenue, 2018-2023
6.2.2 By Region – Global PEG-modified Drugs Revenue, 2024-2029
6.2.3 By Region – Global PEG-modified Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America PEG-modified Drugs Revenue, 2018-2029
6.3.2 US PEG-modified Drugs Market Size, 2018-2029
6.3.3 Canada PEG-modified Drugs Market Size, 2018-2029
6.3.4 Mexico PEG-modified Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe PEG-modified Drugs Revenue, 2018-2029
6.4.2 Germany PEG-modified Drugs Market Size, 2018-2029
6.4.3 France PEG-modified Drugs Market Size, 2018-2029
6.4.4 U.K. PEG-modified Drugs Market Size, 2018-2029
6.4.5 Italy PEG-modified Drugs Market Size, 2018-2029
6.4.6 Russia PEG-modified Drugs Market Size, 2018-2029
6.4.7 Nordic Countries PEG-modified Drugs Market Size, 2018-2029
6.4.8 Benelux PEG-modified Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia PEG-modified Drugs Revenue, 2018-2029
6.5.2 China PEG-modified Drugs Market Size, 2018-2029
6.5.3 Japan PEG-modified Drugs Market Size, 2018-2029
6.5.4 South Korea PEG-modified Drugs Market Size, 2018-2029
6.5.5 Southeast Asia PEG-modified Drugs Market Size, 2018-2029
6.5.6 India PEG-modified Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America PEG-modified Drugs Revenue, 2018-2029
6.6.2 Brazil PEG-modified Drugs Market Size, 2018-2029
6.6.3 Argentina PEG-modified Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa PEG-modified Drugs Revenue, 2018-2029
6.7.2 Turkey PEG-modified Drugs Market Size, 2018-2029
6.7.3 Israel PEG-modified Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia PEG-modified Drugs Market Size, 2018-2029
6.7.5 UAE PEG-modified Drugs Market Size, 2018-2029
7 PEG-modified Drugs Companies Profiles
7.1 Merck Sharp & Dohme
7.1.1 Merck Sharp & Dohme Company Summary
7.1.2 Merck Sharp & Dohme Business Overview
7.1.3 Merck Sharp & Dohme PEG-modified Drugs Major Product Offerings
7.1.4 Merck Sharp & Dohme PEG-modified Drugs Revenue in Global Market (2018-2023)
7.1.5 Merck Sharp & Dohme Key News & Latest Developments
7.2 Baxalta Inc.
7.2.1 Baxalta Inc. Company Summary
7.2.2 Baxalta Inc. Business Overview
7.2.3 Baxalta Inc. PEG-modified Drugs Major Product Offerings
7.2.4 Baxalta Inc. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.2.5 Baxalta Inc. Key News & Latest Developments
7.3 Amgen Inc.
7.3.1 Amgen Inc. Company Summary
7.3.2 Amgen Inc. Business Overview
7.3.3 Amgen Inc. PEG-modified Drugs Major Product Offerings
7.3.4 Amgen Inc. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.3.5 Amgen Inc. Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche PEG-modified Drugs Major Product Offerings
7.4.4 Roche PEG-modified Drugs Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 UCB S.A.
7.5.1 UCB S.A. Company Summary
7.5.2 UCB S.A. Business Overview
7.5.3 UCB S.A. PEG-modified Drugs Major Product Offerings
7.5.4 UCB S.A. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.5.5 UCB S.A. Key News & Latest Developments
7.6 Enzon
7.6.1 Enzon Company Summary
7.6.2 Enzon Business Overview
7.6.3 Enzon PEG-modified Drugs Major Product Offerings
7.6.4 Enzon PEG-modified Drugs Revenue in Global Market (2018-2023)
7.6.5 Enzon Key News & Latest Developments
7.7 Horizon Pharma Plc
7.7.1 Horizon Pharma Plc Company Summary
7.7.2 Horizon Pharma Plc Business Overview
7.7.3 Horizon Pharma Plc PEG-modified Drugs Major Product Offerings
7.7.4 Horizon Pharma Plc PEG-modified Drugs Revenue in Global Market (2018-2023)
7.7.5 Horizon Pharma Plc Key News & Latest Developments
7.8 Biogen Inc.
7.8.1 Biogen Inc. Company Summary
7.8.2 Biogen Inc. Business Overview
7.8.3 Biogen Inc. PEG-modified Drugs Major Product Offerings
7.8.4 Biogen Inc. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.8.5 Biogen Inc. Key News & Latest Developments
7.9 Qilu Pharmaceutical Co., Ltd.
7.9.1 Qilu Pharmaceutical Co., Ltd. Company Summary
7.9.2 Qilu Pharmaceutical Co., Ltd. Business Overview
7.9.3 Qilu Pharmaceutical Co., Ltd. PEG-modified Drugs Major Product Offerings
7.9.4 Qilu Pharmaceutical Co., Ltd. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.9.5 Qilu Pharmaceutical Co., Ltd. Key News & Latest Developments
7.10 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
7.10.1 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Company Summary
7.10.2 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Business Overview
7.10.3 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. PEG-modified Drugs Major Product Offerings
7.10.4 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.10.5 CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Key News & Latest Developments
7.11 Changchun Genescience Pharmaceutical Co., Ltd.
7.11.1 Changchun Genescience Pharmaceutical Co., Ltd. Company Summary
7.11.2 Changchun Genescience Pharmaceutical Co., Ltd. Business Overview
7.11.3 Changchun Genescience Pharmaceutical Co., Ltd. PEG-modified Drugs Major Product Offerings
7.11.4 Changchun Genescience Pharmaceutical Co., Ltd. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.11.5 Changchun Genescience Pharmaceutical Co., Ltd. Key News & Latest Developments
7.12 Xiamen Amoytop Biotech Co., Ltd.
7.12.1 Xiamen Amoytop Biotech Co., Ltd. Company Summary
7.12.2 Xiamen Amoytop Biotech Co., Ltd. Business Overview
7.12.3 Xiamen Amoytop Biotech Co., Ltd. PEG-modified Drugs Major Product Offerings
7.12.4 Xiamen Amoytop Biotech Co., Ltd. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.12.5 Xiamen Amoytop Biotech Co., Ltd. Key News & Latest Developments
7.13 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
7.13.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Summary
7.13.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
7.13.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PEG-modified Drugs Major Product Offerings
7.13.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.13.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Key News & Latest Developments
7.14 Hansoh Pharmaceuticak Group Co.,Ltd.
7.14.1 Hansoh Pharmaceuticak Group Co.,Ltd. Company Summary
7.14.2 Hansoh Pharmaceuticak Group Co.,Ltd. Business Overview
7.14.3 Hansoh Pharmaceuticak Group Co.,Ltd. PEG-modified Drugs Major Product Offerings
7.14.4 Hansoh Pharmaceuticak Group Co.,Ltd. PEG-modified Drugs Revenue in Global Market (2018-2023)
7.14.5 Hansoh Pharmaceuticak Group Co.,Ltd. Key News & Latest Developments
7.15 SunBio
7.15.1 SunBio Company Summary
7.15.2 SunBio Business Overview
7.15.3 SunBio PEG-modified Drugs Major Product Offerings
7.15.4 SunBio PEG-modified Drugs Revenue in Global Market (2018-2023)
7.15.5 SunBio Key News & Latest Developments
7.16 Xiamen Sano banger Biotechnology Co., Ltd
7.16.1 Xiamen Sano banger Biotechnology Co., Ltd Company Summary
7.16.2 Xiamen Sano banger Biotechnology Co., Ltd Business Overview
7.16.3 Xiamen Sano banger Biotechnology Co., Ltd PEG-modified Drugs Major Product Offerings
7.16.4 Xiamen Sano banger Biotechnology Co., Ltd PEG-modified Drugs Revenue in Global Market (2018-2023)
7.16.5 Xiamen Sano banger Biotechnology Co., Ltd Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer